$LGVW to merge w/@ButterflyNetInc -- a disruptor in ultrasound.

Learned about it a few days ago & had a chance to dig in.

A thread 👇.
The product: "Butterfly IQ+"
-Puts ultrasound on a semiconductor
-Ushers in era of hand-held ultrasound
-Linear, curvilinear & phased array ultrasound probe all in 1
-Connects hardware w/integrated software, AI & tele-guidance to drive faster, smarter, less costly medical imaging
1. Notes from Dr. Jonathon Rothberg -- Founder & Chairman

The resume
-Pioneered a process to sequence genomes on a semiconductor
-Launched field of next-gen sequencing
-Won a Presidential Medal of Tech & innovation… casual
Dr. Rothberg continued:

“I knew life had transformed when computing was put on a chip… I saw the power of Moore’s law & envisioned how it could be brought to DNA sequencing.”
Dr. Rothberg continued:

“I discovered majority of 🌏 had no access to medical imaging.”

What'd he do?

Put ultrasound on a chip.

“Today Butterfly IQ+ has the broadest FDA clearance for a single ultrasound probe ever... it's the world’s 1st & only full-body ultrasound system."
2. Dr. John Martin -- CMO

“Ultrasound is the fastest growing medical imaging modality.”

“For 50 years, ultrasound used the same piezoelectric crystal tech driving complexity & cost higher."

👆Means patients "wait for imaging in dedicated centers or for carts to come bedside.”
3. Notes from Gioel Molinari -- President

IQ+'s 3-staged approach to value:

a) ultrasound on a chip -- replaces piezoelectric tech w/9000 micro-transducers (tiny drums emitting & receiving ultrasound)
--Frees ultrasound to be
---Scalable
---Portable
---Affordable

b&c) 👇
b) Invested in software & AI tools to automate measurements & aid professionals in decision-making

c) Butterfly Enterprise: The IQ+ operating system (OS) for point of care ultrasound ensuring:
-quality control
-electronic medical record (EMR) integration
Molinari continued:

IQ+
a) offers 20 clinical sets ranging from shallow to deep imaging
--change depth setting w/phone app
--uses 1 probe; competition needs 2-3
b) performs a volumetric bladder scan
--gages if catheterization needed
--had been determined w/time intervals alone
Molinari continued:

c) "Don’t need to listen to the heart with a stethoscope… can image the heart in real time"

d) Demonstrated uploading results into patient records

e) Hit on their "imaging virtuous cycle" -- IQ+ improves as more data boosts AI & tele-guide capabilities
Final notes from Molinari:

“We hope to introduce a product to be used by patients to self-scan ultrasound in the home to send to doctors in real time.”

“We hope to continue miniaturizing our chip to enable wearable medical imaging… using our partnership with $TSM.”
4. Highlights from Laurent Faracci -- CEO

The market
-TAM of $8B & growing
-40M global HC workers to ultimately target; 8M initially

“By bringing imaging to the patient, we allow access beyond traditional imaging centers & broaden the settings for ultrasound”
Faracci continued:

“Plan to update our hardware every 2 years and to push out monthly software update to enhance utility”

Recent examples:
-Launch of "Needle Viz" for confident, ultrasound-guided needle insertion
-“Fast 3D bladder rendering”
-“Many more soon to go”
Faracci continued -- wearables

“In 2023 & subject to regulatory authorization… we plan to enter the wearables market representing 100M chronic patients in the USA alone”

"Our wearable patch will capitalize on momentum from higher-tier software & at-home monitoring trends”
Final tidbit from Faracci:

“This year we launched a salesforce to scale adoption… many of whom are practitioners already using butterfly today.”
5. Highlights from Stephanie Fielding -- CFO

a) $44M in 2020 revs from “individual professionals & small groups"
b) Will scale adoption w/large enterprises starting in '21
c) Expect a 66% CAGR through 2024
--$334M in 2024 revs
--Includes little future wearables contribution
Fielding continued:

Profitability:
a) Gross profit margin (GPM) to inflect from negative to 40% in 2021 via moving from developmental fab manufacturer to $TSM
b) GPM target of 70%
c) Expect free cash by 2024

Wearables to conservatively contribute 10% to revs by 2024.
Fielding final notes:

“Capital from the transaction covers planned investments, supports planned transition to free cash & allows for additional capital allocation.”

“Software revenue is expected to reach 40-50% of total revenues by the back end of the decade”
6. Deal structure BASED ON $17/share

a) EV roughly $2.85B
b) $175M PIPE @ $10/share
-- $THC & Fidelity part of PIPE
c) 23.3M outstanding options

NOTE: valuation slide below is off... based on $10/share not current price -- now it's more like 18x 2022 EV/Revs not 10.6x
7. Competitive landscape -- thanks @Nick_HuynhMPLS

Some can come close to IQ+ on cost. None rival it on probe functionality.

IQ+ is the only all in 1 linear, curvilinear & phased array probe (AKA it can image @ various depths & so perform more tests)

IQ+ user on-boarding:

-Complex procedures take a few hours & a handful of exams to master
-Per The Journal of Family Medicine: A Lung exam w/IQ+ takes hours to learn
-For trained users, Butterfly built a learning management system to provide scalable education
8. @Glassdoor reviews are limited & fine but not amazing:

glassdoor.com/Reviews/Butter…

All private shareholders (including Baillie Gifford & the Gates Foundation) are rolling their equity into the public company.
1 more concern:

Image quality.

Chip-based ultrasound was released by @HitachiGlobal in 2009.

It struggled w/quality & offered just 1 depth.

Butterfly offers many depths but some worry all chip-based ultrasound will struggle w/image quality.

@ButterflyNetInc disagrees.
Summary:

-Strong IQ+ value-prop
-IQ+ is cleared
-Integrated, high-margin software business built in
-Leadership impressive
-Wearables = larger pursuit not factored into guidance
-High risk, high reward name

VERY small position -- .5% of holdings

Long $LGVW

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Brad Freeman

Brad Freeman Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @StockMarketNerd

30 Aug
Weekend theme: S-1s

peaked my interest.

THREAD TIME!
Problem w/healthcare:

"No guidance for what healthcare should cost with or without insurance" -Co-CEO Doug Hirsch

Leads to higher costs so that in USA:
-2/3 avoid care entirely
-20-30% of scripts are left at counter
-25% have no doc
Resulting unfortunate consequences:

For us: American dies every 4 mins from not taking prescribed medicine as directed

For Health system: 30% of ER visits could have been treated in other care settings. ER visits are expensive for all parties.

For pharmacies: Loss of sales
Read 20 tweets
19 Aug
Why I'm sipping on $LMND

THREAD TIME

@Lemonade_Inc A digitally-native insurance platform featuring

a) AI & machine learning to more accurately price risk & more affordably price plans
b) Philanthropy to make a shady industry friendlier
c) A quick, transparent buying process
The machine is learning:

In 2017: $LMND AI bots (Jim & Maya) handled 6% of inquiries.

Today 32%

There is every reason to believe the % will continue rising for this less than 4 y/o company.

Fosters lower customer acquisition cost that company passes on to users. (see below)
AI edge:

$LMND loss ratios improve w/scale; opposite of competition.

(Loss ratio=$ paid in claims/$ collected in premiums)

$LMND: .67

Industry ave: .82 (low is 👍)

Machines > human mind @ scaling

A young company used AI to be 15% better at pricing risk than 100 y/o firms.
Read 12 tweets
16 Aug
My investment philosophy (THREAD)

A) Identify stocks based on financial metrics such as:

rev growth/margin profile/op fcf & fcf trends/bs health/capital mgmt

Is growth powered solely by more opex, debt or equity dilution?

Is there any operating leverage apparent in business?
B) Study quality of products, competitive landscape, innovation pipeline, mgmt quality, & try to identify a strong moat.

Ask myself (& others) will products be growingly needed over 20 yrs? Is the company in a position to fill added demand?

Is it being disrupted or disrupting?
C) Listen to several past earnings calls & executive interviews to gage how timely & successful mgmt is w/executing stated goals.

Were predictions reliable or did they consistently miss the mark?

How smoothly are ops carried out?

Can I trust this mgmt team w/my $?
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!